Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756 | 0.83 | BACE1 (0.71) | BACE1 | |
| SCHEMBL14322009 | 0.81 | BACE1 (0.59) | BACE1 | |
| SCHEMBL9424 | 0.77 | BACE1 (0.56) | BACE1ABL1CNR1MAPK14 | |
| SCHEMBL9425 | 0.77 | BACE1 (0.56) | BACE1ABL1CNR1MAPK14 | |
| SCHEMBL17620296 | 0.75 | BACE1 (1.00) | BACE1 | |
| SCHEMBL9288 | 0.74 | BACE1 (1.00) | BACE1 | |
| SCHEMBL17620371 | 0.72 | BACE1 (1.00) | BACE1 | |
| SCHEMBL9464 | 0.71 | BACE1 (0.76) | BACE1HPGD | |
| SCHEMBL17620305 | 0.71 | BACE1 (1.00) | BACE1 | |
| SCHEMBL17620329 | 0.70 | BACE1 (0.80) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885ABL1 3563/4885HPGD 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.